Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04628780 · OUTCOME

Duration of Response (DOR) Based on Investigator Assessment in Participants With Confirmed Response

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors · Source last updated 2024-07-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline through up to 2 years or until disease progression

What was measured

DOR is defined as the time from first documentation of CR or PR to date of first documentation of objective progression, or death due to any cause, or time of censoring, whichever occurred first.

Analysis population: The full analysis set included all enrolled participants.

Groups in this outcome

PF-07209960 20 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.

PF-07209960 30 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
PF-07209960 20 mg SC1
PF-07209960 30 mg SC1

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
PF-07209960 20 mg SC9.5Not reportedNANAOnly 1 participant had DOR record
PF-07209960 30 mg SC3Not reportedNANAOnly 1 participant had DOR record
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Only 1 participant had DOR record
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        9.5
      2. comment
        Only 1 participant had DOR record
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      1
    units
    Participants
description
DOR is defined as the time from first documentation of CR or PR to date of first documentation of objective progression, or death due to any cause, or time of censoring, whichever occurred first.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.
    id
    OG000
    title
    PF-07209960 20 mg SC
  2. description
    Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.
    id
    OG001
    title
    PF-07209960 30 mg SC
param Type
MEDIAN
population Description
The full analysis set included all enrolled participants.
reporting Status
POSTED
time Frame
Baseline through up to 2 years or until disease progression
title
Duration of Response (DOR) Based on Investigator Assessment in Participants With Confirmed Response
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice